Advertisement
Screener

Eton Pharmaceuticals, Inc. (ETON) Amortization of Leased Asset

3.0 / 5 stars · 30/50 Roast Me

Eton Pharmaceuticals, Inc. Amortization of Leased Asset

Eton Pharmaceuticals, Inc. (ETON) reported Amortization of Leased Asset of $20.00 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-16.

Discontinued › Expense Statement › Operating Expenses

us-gaap:AmortizationOfLeasedAsset · last filed 2021-11-16

  • Eton Pharmaceuticals, Inc. amortization of leased asset for the quarter ending 2021-09-30 was $20.00K, a 39.39% decline year-over-year.
  • Eton Pharmaceuticals, Inc. amortization of leased asset for the quarter ending 2021-06-30 was $20.00K, a 39.39% decline year-over-year.
  • Eton Pharmaceuticals, Inc. amortization of leased asset for the quarter ending 2020-09-30 was $33.00K.
  • Eton Pharmaceuticals, Inc. amortization of leased asset for the quarter ending 2020-06-30 was $33.00K, a 44.07% decline year-over-year.
Period endAmortization of Leased Asset 3 monthAmortization of Leased Asset 6 monthAmortization of Leased Asset 9 month
2021-09-30$20.00K
10-Q · filed 2021-11-16
$40.00K
derived: sum of 2 quarters · filed 2021-11-16
$69.00K
10-Q · filed 2021-11-16
2021-06-30$20.00K
10-Q · filed 2021-08-16
$49.00K
10-Q · filed 2021-08-16
2020-09-30$33.00K
10-Q · filed 2021-11-16
$66.00K
derived: sum of 2 quarters · filed 2021-11-16
$97.00K
10-Q · filed 2021-11-16
2020-06-30$33.00K
10-Q · filed 2021-08-16
$64.00K
10-Q · filed 2021-08-16
2019-06-30$59.00K
10-Q · filed 2020-08-12
$30.00K
10-Q · filed 2020-08-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xencor Inc (XNCR)United States$1.776B-7.33
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Septerna, Inc. (SEPN)United States$1.783B-63.01
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
ANI PHARMACEUTICALS INC (ANIP)United States$1.810B18.77
COMPASS Pathways plc (CMPS)$1.812B-4.87
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20